Organization · Venture Capital
Avalon BioVentures
Avalon BioVentures is a San Diego-based biotech venture capital firm focused on early-stage life sciences innovations. It combines capital investment with operational support through its ABV Accelerator to build pioneering biotech companies.
Overview
What Avalon BioVentures does
What Avalon BioVentures is
Avalon BioVentures is a San Diego-based biotech venture capital firm focused on early-stage life sciences innovations. It combines capital investment with operational support through its ABV Accelerator to build pioneering biotech companies.
How it participates in the startup ecosystem
The current public profile supports funder and program host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1983
- Approximate age
- About 43 years
- Structured capabilities
- Funder · Program host
- Last reviewed
- May 1, 2026
Official channels
Find Avalon BioVentures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Avalon BioVentures as a funder
Investment thesis
Avalon BioVentures focuses on identifying early-stage scientific opportunities and forming companies around disruptive technologies, emphasizing first-in-class innovation and hands-on operational support.
Focus narrative
Avalon BioVentures invests in early-stage life sciences innovations, particularly those that are first-in-class and address significant medical needs. The organization seeks out opportunities that are often too early for other investors and is willing to take on scientific risks. Their investment strategy includes a fully integrated operational model through the ABV Accelerator, which provides portfolio companies with access to scientific, operational, and financial resources to expedite development timelines and optimize capital efficiency.
Value beyond capital
Avalon BioVentures provides a comprehensive support system for its portfolio companies, including capital, mentorship, and access to operational resources through the ABV Accelerator. This hands-on approach helps expedite development timelines and optimize capital efficiency, making it particularly valuable for scientific founders who need more than just funding.
Focus and fit
- Stages
- Pre-seed · Seed · Friends and Family · Angel · Accelerator
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Synthorx, Inc., Jnana Therapeutics, and Nerio Therapeutics
Portfolio context
Notable companies associated with Avalon BioVentures include: Janux Therapeutics: Founded by David Campbell, Ph.D.; Synthorx, Inc.: Formerly led by Laura Shawver, Ph.D., and sold to Sanofi for $2.5 billion; Sitari, Inc.: Founded by Chaitan Khosla, Ph.D., focusing on treatments for celiac disease; Fortis Therapeutics, Inc.: Founded by Bin Liu, Ph.D., which advanced discoveries into clinical trials; Valora: Supported by Carolyn Bertozzi, Ph.D., with funding and strategic guidance from Avalon.
Capability profile
Avalon BioVentures as a program host
Program thesis
Avalon BioVentures focuses on investing in and building pioneering biotech companies that address critical unmet medical needs.
Focus narrative
Avalon BioVentures invests in early-stage life sciences innovations, particularly those that are first-in-class and address significant medical needs. They actively seek opportunities that are often too early for other investors and are willing to take on scientific risks. Their investment strategy includes a fully integrated operational model through the ABV Accelerator, which provides portfolio companies with access to essential resources to expedite development timelines.
Value and support
Founders receive capital investment, mentorship, and access to a network of scientific and operational resources through the ABV Accelerator, which helps optimize capital efficiency and accelerate development timelines.
Availability
- Application state
- Not published
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Sectors
- Biotech & Life Sciences
- Regions
- North America
Alumni and track record
Alumni context
Notable alumni companies include Janux Therapeutics, Synthorx, Inc. (sold to Sanofi for $2.5 billion), Sitari, Inc. (focused on celiac disease treatments), Fortis Therapeutics, Inc. (advanced discoveries into clinical trials), and Valora (supported with funding and strategic guidance).
Common questions
What to know about Avalon BioVentures
Upseed classifies Avalon BioVentures under the Venture Capital organization type. Its current public profile includes funder and program host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.